Crossmark

Management Recommendations for Dupilumab Partial and Non-durable Responders in Atopic Dermatitis

Crossref DOI link: https://doi.org/10.1007/s40257-019-00436-8

Published Online: 2019-03-27

Published Print: 2019-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Hendricks, Aleksi J.

Lio, Peter A.

Shi, Vivian Y.
License Information

Text and Data Mining valid from 2019-03-27
More Information

Article History

First Online: 27 March 2019

Compliance with Ethical Standards

:

: No funding sources.

: Vivian Shi is a stock shareholder of Dermveda, has served as an advisor for Sanofi Genzyme/Regeneron, AbbVie, Novartis, SUN Pharma, Pfizer, Menlo Therapeutics, Burt’s Bees, GpSkin, the National Eczema Association and Global Parents for Eczema Research, is an investigator for AbbVie, Regeneron, Novartis, and LEO Pharma, and has received research funding from the Foundation for Atopic Dermatitis and Skin Actives Scientific. There were no incentives or transactions financial or otherwise relevant to this manuscript. Peter Lio has served as an investigator, speaker, advisory board member, and consultant for Sanofi Genzyme/Regeneron. There were no incentives or transactions financial or otherwise relevant to this manuscript. Aleksi Hendricks has no potential conflicts of interest to declare.